Article ID Journal Published Year Pages File Type
3925920 European Urology 2008 7 Pages PDF
Abstract

ObjectiveA broad spectrum of options is available for treatment of Peyronie's disease; however, the effects of minimally invasive therapy are generally inadequate. Although useful, oral drugs must be administered at onset of the disease. Only a few patients request penile surgery. Therefore, new medical treatments for Peyronie's disease are needed. A better understanding of the pathogenesis of Peyronie's disease is required to facilitate development of these new medical treatments. Several studies have described an increased level of TGF-β in the fibrotic plaques of patients with Peyronie's disease, underscoring this important signalling pathway in the onset and/or development of Peyronie's disease.MethodsPlaque biopsies were taken from 16 patients with Peyronie's disease. Furthermore, 7 patients without Peyronie's disease were biopsied to provide control material. Fibroblasts were cultured from biopsy tissue, and cultured fibroblasts were stimulated with TGF-β1, BMP-2, IFN-γ, and IFN-γ combined with one of the other stimuli. Protein was extracted from treated fibroblasts and prepared for immunoblots. The membranes were probed for phosphorylated Smad and total Smad to indicate activation of TGF-β signalling.ResultsAn agonistic effect of IFN-γ on TGF-β signalling was observed. Stimulation with TGF-β1 increased levels of phospho-Smad2 and phospho-Smad3. After stimulation with TGF-β1 and IFN-γ combined, the levels of phospho-Smads were higher than those observed with stimulation withTGF-β1 alone.ConclusionsThe profibrotic effect of TGF-β1 is enhanced by IFN-γ in fibroblasts from patients with Peyronie's disease. The inhibitory effects of IFN-γ on the TGF-β pathway do not appear in Peyronie's disease. Therefore, IFN-γ cannot be taken as a useful tool in the therapy of Peyronie's disease.

Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Authors
, , , , , ,